Albumin-bound paclitaxel in solid tumors: clinical development and future directions

Madappa N Kundranda, Jiaxin Niu, Madappa N Kundranda, Jiaxin Niu

Abstract

Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that was initially developed more than a decade ago to overcome toxicities associated with the solvents used in the formulation of standard paclitaxel and to potentially improve efficacy. Nab-paclitaxel has demonstrated an advantage over solvent-based paclitaxel by being able to deliver a higher dose of paclitaxel to tumors and decrease the incidence of serious toxicities, including severe allergic reactions. To date, nab-paclitaxel has been indicated for the treatment of three solid tumors in the USA. It was first approved for the treatment of metastatic breast cancer in 2005, followed by locally advanced or metastatic non-small-cell lung cancer in 2012, and most recently for metastatic pancreatic cancer in 2013. Nab-paclitaxel is also under investigation for the treatment of a number of other solid tumors. This review highlights key clinical efficacy and safety outcomes of nab-paclitaxel in the solid tumors for which it is currently indicated, discusses ongoing trials that may provide new data for the expansion of nab-paclitaxel's indications into other solid tumors, and provides a clinical perspective on the use of nab-paclitaxel in practice.

Keywords: breast; lung; melanoma; nab-paclitaxel; ovarian; pancreas.

References

    1. Taxotere® (docetaxel) injection concentrate, intravenous infusion (IV) [package insert] Bridgewater, NJ: Sanofi-Aventis; 2013.
    1. Taxol® (paclitaxel) injection [package insert] Princeton, NJ: Bristol-Myers Squibb; 2011.
    1. Abraxane® for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) Summit, NJ: Celgene Corporation; 2014.
    1. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590–1598.
    1. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8(7):1263–1268.
    1. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42(7):665–685.
    1. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer. 1999;81(2):330–335.
    1. Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999;59(7):1454–1457.
    1. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317–1324.
    1. Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. Transl Oncol. 2009;2(2):59–64.
    1. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1–2):271–284.
    1. Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013;170(3):365–372.
    1. Chen N, Li Y, Ye Y, Palmisano M, Chopra R, Zhou S. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol. 2014;54(10):1097–1107.
    1. Li Y, Chen N, Palmisano M, Zhou S. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations. Mol Pharm. 2015;12(4):1308–1317.
    1. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–7803.
    1. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055–2062.
    1. Hirsh V, Okamoto I, Hon JK, et al. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9(1):83–90.
    1. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8(5):1038–1044.
    1. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996;14(6):1858–1867.
    1. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005;23(31):7785–7793.
    1. Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005;23(25):6019–6026.
    1. Socinski MA, Manikhas GM, Stroyakovsky DL, et al. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(6):852–861.
    1. Socinski MA, Langer CJ, Okamoto I, et al. Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(2):314–321.
    1. Socinski MA, Okamoto I, Hon JK, et al. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(9):2390–2396.
    1. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–2413.
    1. Tarceva® (erlotinib) tablets, for oral use [package insert] South San Francisco, CA: Genentech USA, Inc; 2014.
    1. Moore MJ, Goldstein D, Hamm J, et al. National Cancer Institute of Canada Clinical Trials Group Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–1966.
    1. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB., 3rd Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20(15):3270–3275.
    1. Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006;24(27):4441–4447.
    1. Herrmann R, Bodoky G, Ruhstaller T, et al. Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25(16):2212–2217.
    1. Louvet C, Labianca R, Hammel P, et al. GERCOR; GISCAD Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23(15):3509–3516.
    1. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22(18):3776–3783.
    1. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29(34):4548–4554.
    1. Frese KK, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2(3):260–269.
    1. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
    1. Gradishar WJ, Krasnojon D, Cheporov S, et al. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer. 2012;12(5):313–321.
    1. Hidalgo M, Plaza C, Illei PB, et al. SPARC analysis in the phase III MPACT trial of nab-paclitaxel plus gemcitabine vs gemcitabine alone for patients with metastatic pancreatic cancer. Ann Oncol. 2015;25(Suppl 2):ii106.
    1. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27(22):3611–3619.
    1. O’Shaughnessy J, Gradishar WJ, Bhar P, Iglesias J. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat. 2013;138(3):829–837.
    1. Lobo C, Lopes G, Baez O, et al. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2010;123(2):427–435.
    1. Hamilton E, Kimmick G, Hopkins J, et al. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer. 2013;13(6):416–420.
    1. Rugo HS, Barry WT, Moreno-Aspitia A, et al. CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone +/− bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. J Clin Oncol. 2012;30(Suppl) Abstract CRA1002.
    1. Untch M, Jackisch C, Schneeweiss A, et al. A randomized phase III trial comparing nanoparticle-based (nab) paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer GBG 69 (GeparSepto); Presented at: 2014 San Antonio Breast Cancer Symposium; December 9–13 2014; San Antonio, Texas. [Accessed May 7, 2015]. Abstract S2-07. Available from:
    1. Patt D, Liang C, Li L, et al. Safety and efficacy of nab-paclitaxel in patients with metastatic breast cancer: real-world results from a US health insurance database. [Accessed July 9, 2015];J Clin Oncol. 2014 5s(Suppl) Abstract 1075. Available from: .
    1. NCCN Clinical Practice Guidelines in Oncology Breast Cancer V2. 2015. [Accessed March 16, 2015]. [Accessed July 9, 2015]. Available from: . Available from: .
    1. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–1281.
    1. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM, North Central Cancer Treatment Group Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531) Ann Oncol. 2009;20(3):449–453.
    1. Celgene Corporation [website on the Internet] Evaluate risk/benefit of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity) Bethseda, MD: US National Library of Medicine; 2013. [Accessed June 22, 2015]. [updated June 12, 2015]. Available from: . NLM identifier: NCT01881230.
    1. Hofmann D, Nitz U, Gluz O, et al. WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials. 2013;14:261.
    1. West German Study Group [website on the Internet] Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer (ADAPT) Bethseda, MD: US National Library of Medicine; 2013. [Accessed June 22, 2015]. [updated May 18, 2015]. Available from: . NLM identifier: NCT01781338.
    1. Fondazione Michelangelo [website on the Internet] Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer (ETNA) Bethseda, MD: US National Library of Medicine; 2013. [Accessed June 22, 2015]. [updated May 25, 2015]. Available from: . NLM identifier: NCT01822314.
    1. German Breast Group [website on the Internet] Study of nab-paclitaxel in high risk early breast cancer (GAIN-2) Bethseda, MD: US National Library of Medicine; 2012. [Accessed May 4, 2015]. [updated November 26, 2015]. Available from: . NLM identifier: NCT01690702.
    1. Hoffmann-La Roche [website on the Internet] A study of Perjeta (pertuzumab) and Herceptin (trastuzumab) treatment in combination with a taxane in patients with advanced HER2-positive breast cancer. Bethseda, MD: US National Library of Medicine; 2013. [Accessed June 22, 2015]. [updated June 1, 2015]. Available from: . NLM identifier: NCT02019277.
    1. Hoffmann-La Roche [website on the Internet] A study of pertuzumab in combination with Herceptin (trastuzumab) and a taxane in first-line treatment in patients with HER2-positive advanced breast cancer (PERUSE) Bethseda, MD: US National Library of Medicine; 2012. [Accessed June 22, 2015]. [updated June 1, 2015]. Available from: . NLM identifier: NCT01572038.
    1. Howlader N, Noone AM, Krapcho M, editors. SEER Cancer Statistics Review, 1975–2010 [web page on the Internet] Bethesda, MD: National Cancer Institute; 2013. [Accessed June 22, 2015]. [updated June 14, 2013]. Available from:
    1. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002;94(3):173–181.
    1. Langer CJ, Vangel M, Schiller J, et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70–80 yrs) with NSCLC do as well as younger pts (<70) Proc Am Soc Clin Oncol. 2003;22:639.
    1. Lilenbaum RC, Herndon JE, II, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730) J Clin Oncol. 2005;23(1):190–196.
    1. Blanchard EM, Moon J, Hesketh PJ, et al. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol. 2011;6(1):115–120.
    1. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Eastern Cooperative Oncology Group Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008;26(1):60–65.
    1. Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J. 2005;11(6):461–473.
    1. Aymanns C, Keller F, Maus S, Hartmann B, Czock D. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol. 2010;5(2):314–327.
    1. Celgene Corporation Safety and efficacy study of Abraxane in combination with carboplatin to treat advanced NSCL cancer in the elderly (ABOUND 70+) [Accessed May 4, 2015]. Available from: . NLM identifier: NCT02151149.
    1. Cetin K, Ettinger DS, Hei YJ, O’Malley CD. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin Epidemiol. 2011;3:139–148.
    1. NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer. V5. 2015. [Accessed March 16, 2015]. [Accessed July 9, 2015]. Available from: . Available from: .
    1. Celgene Corporation Safety and efficacy study of Abraxane as maintenance treatment after Abraxane plus carboplatin in 1st line stage IIIB/IV squamous cell non-small cell lung cancer (aboundsqm) [Accessed May 4, 2015]. Available from: . NLM identifier: NCT02027428.
    1. NCCN Clinical Practice Guidelines in Oncology Pancreatic Adenocarcinoma. V2. 2015. [Accessed March 16, 2015]. [Accessed July 9, 2015]. Available from: . Available from: .
    1. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–1481.
    1. Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101(6):908–915.
    1. Celgene Corporation [website on the Internet] Nab-paclitaxel and gemcitabine vs gemcitabine alone as adjuvant therapy for patients with resected pancreatic cancer (the “Apact” study) (apact) Bethseda, MD: US National Library of Medicine; 2013. [Accessed June 22, 2015]. [updated June 5, 2015]. Available from: . NLM identifier: NCT01964430.
    1. NewLink Genetics Corporation [website on the Internet] Immunotherapy study in borderline resectable or locally advanced unresectable pancreatic cancer (PILLAR) Bethseda, MD: US National Library of Medicine; 2013. [Accessed May 4, 2015]. [updated March 26, 2015]. Available from: . NLM identifier: NCT01836432.
    1. NCCN Clinical Practice Guidelines in Oncology Melanoma. V2. 2015. [Accessed March 16, 2015]. Available from: .
    1. NCCN Clinical Practice Guidelines in Oncology Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. V1. 2015. [Accessed March 16, 2015]. Available from: .
    1. Hersh EM, O’Day SJ, Ribas A, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010;116(1):155–163.
    1. Kottschade LA, Suman VJ, Amatruda T, III, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1) Cancer. 2011;117(8):1704–1710.
    1. Hersh E, Del Vecchio M, Brown MP, et al. Final overall survival from a phase III trial of nab-paclitaxel vs dacarbazine in chemotherapy-naive patients with metastatic melanoma. J Clin Oncol. 2014;5s(Suppl) Abstract 9045.
    1. Academic and Community Cancer Research United [website on the Internet] Paclitaxel albumin-stabilized nanoparticle formulation and bevacizumab or ipilimumab as first-line therapy in treating patients with stage IV melanoma that cannot be removed by surgery. Bethseda, MD: US National Library of Medicine; 2014. [Accessed June 22, 2015]. [updated June 15, 2015]. Available from: . NLM identifier: NCT02158520.
    1. MD Anderson Cancer Center [website on the Internet] Phase II study of Abraxane plus ipilimumab in patients with metastatic melanoma. Bethseda, MD: US National Library of Medicine; 2013. [Accessed May 4, 2015]. [updated December 18, 2014]. Available from: . NLM identifier: NCT01827111.
    1. Teneriello MG, Tseng PC, Crozier M, et al. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2009;27(9):1426–1431.
    1. Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6(5):229–239.
    1. Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122(1):111–115.
    1. Tillmanns TD, Lowe MP, Walker MS, Stepanski EJ, Schwartzberg LS. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol. 2013;128(2):221–228.
    1. UNC Lineberger Comprehensive Cancer Center [website on the Internet] Induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Bethseda, MD: US National Library of Medicine; 2011. [Accessed May 4, 2015]. [updated February 28, 2014]. Available from: . NLM identifier: NCT01412229.
    1. Chinese Academy of Medical Sciences [website on the Internet] First line chemotherapy for advanced cancer (GC-A-003) Bethseda, MD: US National Library of Medicine; 2013. [Accessed May 4, 2015]. Available from: . NLM identifier: NCT01980810.
    1. MD Anderson Cancer Center [website on the Internet] Abraxane in CIMP-high colorectal and small bowel adenocarcinomas. Bethseda, MD: US National Library of Medicine; 2012. [Accessed May 4, 2015]. [updated February 9, 2015]. Available from: . NLM identifier: NCT01730586.
    1. Ma P, Mumper RJ. Paclitaxel Nano-Delivery Systems: A Comprehensive Review. J Nanomed Nanotechnol. 2013;4(2):1000164.
    1. Celgene Europe Limited . Abraxane [summary of product characteristics] London: European Medicines Agency; [Accessed June 4, 2015]. nd. Available from: .

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다